Sökning: WFRF:(van der Meulen Peter) >
Alpha-PET for Prost...
Alpha-PET for Prostate Cancer: Preclinical investigation using Tb-149-PSMA-617
-
Umbricht, C. A. (författare)
-
Koster, U. (författare)
-
- Bernhardt, Peter, 1966 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för radiofysik,Institute of Clinical Sciences, Department of Radiation Physics
-
visa fler...
-
Gracheva, N. (författare)
-
Johnston, K. (författare)
-
Schibli, R. (författare)
-
van der Meulen, N. P. (författare)
-
Muller, C. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2019-11-28
- 2019
- Engelska.
-
Ingår i: Scientific Reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 9
- Relaterad länk:
-
https://www.nature.c...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- In this study, it was aimed to investigate Tb-149-PSMA-617 for targeted a-therapy (TAT) using a mouse model of prostate-specific membrane antigen (PSMA)-expressing prostate cancer. Tb-149-PSMA-617 was prepared with >98% radiochemical purity (6 MBq/nmol) for the treatment of mice with PSMA-positive PC-3 PIP tumors. Tb-149-PSMA-617 was applied at 1 x 6 MBq (Day 0) or 2 x 3 MBq (Day 0 & Day 1 or Day 0 & Day 3) and the mice were monitored over time until they had reached a pre-defined endpoint which required euthanasia. The tumor growth was significantly delayed in mice of the treated groups as compared to untreated controls (p < 0.05). TAT was most effective in mice injected with 2 x 3 MBq (Day 0 & 1) resulting in a median lifetime of 36 days, whereas in untreated mice, the median lifetime was only 20 days. Due to the beta(+)-emission of Tb-149, tumor localization was feasible using PET/CT after injection of Tb-149-PSMA-617 (5 MBq). The PET images confirmed the selective accumulation of Tb-149-PSMA-617 in PC-3 PIP tumor xenografts. The unique characteristics of Tb-149 for TAT make this radionuclide of particular interest for future clinical translation, thereby, potentially enabling PET-based imaging to monitor the radioligand's tissue distribution.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinsk bioteknologi -- Biomedicinsk laboratorievetenskap/teknologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Medical Biotechnology -- Biomedical Laboratory Science/Technology (hsv//eng)
Nyckelord
- radionuclide therapy
- radioligand therapy
- membrane antigen
- in-vivo
- dosimetry estimate
- long-term
- inhibitors
- Science & Technology - Other Topics
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas